Literature DB >> 29774375

[Successful treatment of acquired hemophilia A with recombinant porcine factor VIII].

K Trautmann-Grill1, O Tiebel2, K Hölig3, U Platzbecker3.   

Abstract

Acquired hemophilia A is a rare, potentially life-threatening disease resulting from autoantibodies against coagulation factor VIII. We report the case of a patient with acquired hemophilia A and severe bleeding after incision of a peritonsillar abscess. Treatment with high dose factor VIII and recombinant activated factor VII failed to control bleeding. However, a single infusion of recombinant porcine factor VIII stopped bleeding efficiently and resulted in measurable factor VIII levels.

Entities:  

Keywords:  Acquired hemophilia A; Recombinant activated factor VII; Recombinant porcine factor VIII

Mesh:

Substances:

Year:  2018        PMID: 29774375     DOI: 10.1007/s00063-018-0444-8

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  5 in total

1.  Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy.

Authors:  M Stemberger; P Möhnle; J Tschöp; L Ney; M Spannagl; Martin Reincke
Journal:  Haemophilia       Date:  2016-08-01       Impact factor: 4.287

2.  Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.

Authors:  M D Tarantino; A Cuker; B Hardesty; J C Roberts; M Sholzberg
Journal:  Haemophilia       Date:  2016-08-10       Impact factor: 4.287

Review 3.  How I manage patients with acquired haemophilia A.

Authors:  Douglas W Sborov; George M Rodgers
Journal:  Br J Haematol       Date:  2013-02-04       Impact factor: 6.998

4.  International recommendations on the diagnosis and treatment of patients with acquired hemophilia A.

Authors:  Angela Huth-Kühne; Francesco Baudo; Peter Collins; Jørgen Ingerslev; Craig M Kessler; Hervé Lévesque; Maria Eva Mingot Castellano; Midori Shima; Jean St-Louis
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

5.  Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.

Authors:  R Kruse-Jarres; J St-Louis; A Greist; A Shapiro; H Smith; P Chowdary; A Drebes; E Gomperts; C Bourgeois; M Mo; A Novack; H Farin; B Ewenstein
Journal:  Haemophilia       Date:  2015-01-27       Impact factor: 4.287

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.